DNA nanoparticle-mediated ABCA4 delivery rescues Stargardt dystrophy in mice
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Mutations in the photoreceptor-specific flippase ABCA4 are associated with Stargardt disease and many other forms of retinal degeneration that currently lack curative therapies. Gene replacement is a logical strategy for ABCA4-associated disease, particularly given the current success of traditional viral-mediated gene delivery, such as with adeno-associated viral (AAV) vectors. However, the large size of the ABCA4 cDNA (6.8 kbp) has hampered progress in the development of genetic treatments. Nonviral DNA nanoparticles (NPs) can accommodate large genes, unlike traditional viral vectors, which have capacity limitations. We utilized an optimized DNA NP technology to subretinally deliver ABCA4 to Abca4-deficient mice. We detected persistent ABCA4 transgene expression for up to 8 months after injection and found marked correction of functional and structural Stargardt phenotypes, such as improved recovery of dark adaptation and reduced lipofuscin granules. These data suggest that DNA NPs may be an excellent, clinically relevant gene delivery approach for genes too large for traditional viral vectors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Outstanding studies from Naash and colleagues showed that rod-shaped CK30-PEG (polyethylene glycol)-compacted NPs effectively transfected both RPE and photoreceptors and showed efficacious gene therapy of Rpe65−/− (retinal pigment epithelium 65; model of LCA) and Abca4−/− (Stargardt Disease) mice [39,40,41].”
From The Ocular Gene Delivery Landscape (2021) · cites this paper as [39]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Generally, these methods carry low risk of immune responses commonly associated with viral delivery [44,63,64].”
From Viral Delivery Systems for CRISPR (2019) · cites this paper as [63]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Single-molecule DNA nanoparticles compacted by polyethylene glycol (PEG)-substituted lysine peptides (CK30-PEG) have been used to carry payloads up to 20 kb in size,82,83 with several groups demonstrating their safety in BALB/c mice and rds+/− Rho-/- or Abca4-/- mouse models of retinal degeneration.82–86”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [86]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Weng, J., Mata, N. L., Azarian, S. M., Tzekov, R. T., Birch, D. G., & Travis, G. H. (1999) · Cell · doi:10.1016/s0092-8674(00)80602-9 · Cited by 881 · cited 1×
“Given the packaging capacity of our NPs, we evaluated whether they could express the large ABCA4 therapeutic gene and mediate improvement in a Stargardt disease model (15).”
Konstan, M. W., Davis, P. B., Wagener, J. S., Hilliard, K. A., Stern, R. C., Milgram, L. J. H., Kowalczyk, T. H., Hyatt, S. L., Fink, T. L., Gedeon, C. R., et al. (2004) · Human Gene Therapy · doi:10.1089/hum.2004.15.1255 · Cited by 298
Self-citationAllocca, M., Doria, M., Petrillo, M., Colella, P., Garcia-Hoyos, M., Gibbs, D., Kim, S. R., Maguire, A., Rex, T. S., Di Vicino, U., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34316 · Cited by 292 · cited 1×
“(12); however, subsequent reports demonstrated that the AAVs employed contained a heterogenous mix of DNA, not intact ABCA4 expression cassettes (13).”
Kong, J., Kim, S.-R., Binley, K., Pata, I., Doi, K., Mannik, J., Zernant-Rajang, J., Kan, O., Iqball, S., Naylor, S., et al. (2008) · Gene Therapy · doi:10.1038/gt.2008.78 · Cited by 215
Biochemical defects in ABCR protein variants associated with human retinopathies
Sun, H., Smallwood, P. M., & Nathans, J. (2000) · Nature Genetics · doi:10.1038/79994 · Cited by 203
Nanoparticles of Compacted DNA Transfect Postmitotic Cells
Liu, G., Li, D., Pasumarthy, M. K., Kowalczyk, T. H., Gedeon, C. R., Hyatt, S. L., Payne, J. M., Miller, T. J., Brunovskis, P., Fink, T. L., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305776200 · Cited by 190
Self-citationTransfection of airway epithelium by stable PEGylated poly-l-lysine DNA nanoparticles in vivo
Ziady, A.-G., Gedeon, C. R., Miller, T., Quan, W., Payne, J. M., Hyatt, S. L., Fink, T. L., Muhammad, O., Oette, S., Kowalczyk, T., et al. (2003) · Molecular Therapy · doi:10.1016/j.ymthe.2003.07.007 · Cited by 165
Self-citationFink, T. L., Klepcyk, P. J., Oette, S. M., Gedeon, C. R., Hyatt, S. L., Kowalczyk, T. H., Moen, R. C., & Cooper, M. J. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302761 · Cited by 139 · cited 1×
“Studies using luciferase reporter vectors ranging in size from 5.3 to 20.2 kbp (generated by introducing λ -bacteriophage DNA fragments into the parent plasmid) demonstrated comparable gene expression regardless of vector size, suggesting that these NPs could deliver large genes (10).”
InfluentialSelf-citationCai, X., Conley, S. M., Nash, Z., Fliesler, S. J., Cooper, M. J., & Naash, M. I. (2010) · The FASEB Journal · doi:10.1096/fj.09-139147 · Cited by 120
Self-citationCai, X., Nash, Z., Conley, S. M., Fliesler, S. J., Cooper, M. J., & Naash, M. I. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005290 · Cited by 109 · cited 3×
“They have recently been used to mediate phenotypic rescue in rodent models of retinitis pig-mentosa, Parkinson disease, and cystic fibrosis, and were safely employed in a phase I/II clinical trial for cystic fibrosis (2, 8, 9).”
Self-citation
Research works printed but not linked: 1
- Glushakova, 2006, Mol Vis., 12, 298
Cited by
Cremers, F. P. M., Lee, W., Collin, R. W. J., & Allikmets, R. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100861 · Cited by 315
Role of ABC transporters in lipid transport and human disease
Tarling, E. J., Vallim, T. Q. D. A., & Edwards, P. A. (2013) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.01.006 · Cited by 301
Viral Delivery Systems for CRISPR
Xu, C. L., Ruan, M. Z. C., Mahajan, V. B., & Tsang, S. H. (2019) · Viruses · doi:10.3390/v11010028 · Cited by 277
“Generally, these methods carry low risk of immune responses commonly associated with viral delivery [44,63,64].”
BackgroundEffective delivery of large genes to the retina by dual AAV vectors
Trapani, I., Colella, P., Sommella, A., Iodice, C., Cesi, G., de Simone, S., Marrocco, E., Rossi, S., Giunti, M., Palfi, A., et al. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201302948 · Cited by 269
“In addition, Abca4 (cid:1) / (cid:1) mice also show delayed recovery from light desensitization (Weng et al , 1999; Maiti et al , 2006; Allocca et al , 2008; Radu et al , 2008; Han et al , 2012).”
A comprehensive review of retinal gene therapy
Boye, S. E., Boye, S. L., Lewin, A. S., & Hauswirth, W. W. (2013) · Molecular Therapy · doi:10.1038/mt.2012.280 · Cited by 262
Non-viral gene therapy: Gains and challenges of non-invasive administration methods
Foldvari, M., Chen, D. W., Nafissi, N., Calderon, D., Narsineni, L., & Rafiee, A. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.12.012 · Cited by 238
Gill, J. S., Georgiou, M., Kalitzeos, A., Moore, A. T., & Michaelides, M. (2019) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2018-313278 · Cited by 199
Early and late stage gene therapy interventions for inherited retinal degenerations
Botto, C., Rucli, M., Tekinsoy, M. D., Pulman, J., Sahel, J.-A., & Dalkara, D. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.100975 · Cited by 190
“…as transgene transported by AAV, promoter in front of expressed transgene, serotype of AAV, the dose of AAV or injection route, it has been used successfully for long term gene expression in several animal models and has shown efficacy results for a decade in the clinic(Hastie and Samulski, 2015).”
BackgroundInfluentialInherited retinal diseases: Therapeutics, clinical trials and end points—A review
Georgiou, M., Fujinami, K., & Michaelides, M. (2021) · Clinical & Experimental Ophthalmology · doi:10.1111/ceo.13917 · Cited by 171
The Status of RPE65 Gene Therapy Trials: Safety and Efficacy
Pierce, E. A., & Bennett, J. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017285 · Cited by 150
Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions
Drag, S., Dotiwala, F., & Upadhyay, A. K. (2023) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.64.7.39 · Cited by 145
Causes and consequences of inherited cone disorders
Roosing, S., Thiadens, A. A. H. J., Hoyng, C. B., Klaver, C. C. W., den Hollander, A. I., & Cremers, F. P. M. (2014) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2014.05.001 · Cited by 162
Macular dystrophies: Clinical and imaging features, molecular genetics and therapeutic options
Rahman, N., Georgiou, M., Khan, K. N., & Michaelides, M. (2020) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2019-315086 · Cited by 139
Let There Be Light: Gene and Cell Therapy for Blindness
Dalkara, D., Goureau, O., Marazova, K., & Sahel, J.-A. (2016) · Human Gene Therapy · doi:10.1089/hum.2015.147 · Cited by 129
Charbel Issa, P., Barnard, A. R., Singh, M. S., Carter, E., Jiang, Z., Radu, R. A., Schraermeyer, U., & MacLaren, R. E. (2013) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.13-11688 · Cited by 127
Seeing the light after 25 Years of retinal gene therapy
Trapani, I., & Auricchio, A. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.06.006 · Cited by 124
Georgiou, M., Robson, A. G., Fujinami, K., de Guimarães, T. A. C., Fujinami‐Yokokawa, Y., Varela, M. D., Pontikos, N., Kalitzeos, A. A., Mahroo, O. A., Webster, A. R., et al. (2024) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101244 · Cited by 137
Rajala, A., Wang, Y., Zhu, Y., Ranjo-Bishop, M., Ma, J.-X., Mao, C., & Rajala, R. V. S. (2014) · Nano Letters · doi:10.1021/nl502275s · Cited by 117
Retinoids and Retinal Diseases
Kiser, P. D., & Palczewski, K. (2016) · Annual Review of Vision Science · doi:10.1146/annurev-vision-111815-114407 · Cited by 108
“Nonviral DNA nanoparticles, lacking the size limitations associated with AAV vectors, have also been successfully employed for delivering ABCA4 into the retinas of Abca4−/− mice (Han et al. 2012).”
MethodStructure and function of ABCA4 and its role in the visual cycle and Stargardt macular degeneration
Molday, R. S., Garces, F. A., Scortecci, J. F., & Molday, L. L. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.101036 · Cited by 107
Nanoparticle-based technologies for retinal gene therapy
Adijanto, J., & Naash, M. I. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.12.028 · Cited by 107
Self-citationUSH2A-retinopathy: From genetics to therapeutics
Toualbi, L., Toms, M., & Moosajee, M. (2020) · Experimental Eye Research · doi:10.1016/j.exer.2020.108330 · Cited by 116
Thompson, D. A., Ali, R. R., Banin, E., Branham, K. E., Flannery, J. G., Gamm, D. M., Hauswirth, W. W., Heckenlively, J. R., Iannaccone, A., Jayasundera, K. T., et al. (2015) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.14-16049 · Cited by 101
Therapeutic and Safety Considerations of Nanoparticle-Mediated Drug Delivery in Pregnancy
Keelan, J. A., Leong, J. W., Ho, D., & Iyer, K. S. (2015) · Nanomedicine · doi:10.2217/nnm.15.48 · Cited by 97
Lipid Nanoparticles for Ocular Gene Delivery
Wang, Y., Rajala, A., & Rajala, R. (2015) · Journal of Functional Biomaterials · doi:10.3390/jfb6020379 · Cited by 93
“Compacted DNA nanoparticles formulated with polyethylene glycol-substituted polylysine have been used for gene therapy in mouse models of eye diseases [5–8].”
BackgroundMethodAn AAV Dual Vector Strategy Ameliorates the Stargardt Phenotype in Adult Abca4 −/− Mice
McClements, M. E., Barnard, A. R., Singh, M. S., Charbel Issa, P., Jiang, Z., Radu, R. A., & MacLaren, R. E. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.156 · Cited by 92
Retinal Angiogenesis in the Ins2 Akita Mouse Model of Diabetic Retinopathy
Han, Z., Guo, J., Conley, S. M., & Naash, M. I. (2012) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.12-10959 · Cited by 105
Self-citationTreatment of ocular disorders by gene therapy
Solinís, M. Á., del Pozo-Rodríguez, A., Apaolaza, P. S., & Rodríguez-Gascón, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.12.022 · Cited by 88
Suprachoroidal delivery of viral and nonviral gene therapy for retinal diseases
Kansara, V., Muya, L., Wan, C.-R., & Ciulla, T. A. (2020) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2019.0126 · Cited by 84
“Furthermore, suprachoroidal nonviral gene delivery could lead to repeatable nonsurgical in-office gene therapy for disorders, such as Stargardt or Usher Syndrome, with transgenes greater than the carrying capacity of AAVs.”
BackgroundInfluentialGene therapy for retinal disease
McClements, M. E., & MacLaren, R. E. (2013) · Translational Research · doi:10.1016/j.trsl.2012.12.007 · Cited by 80
“Nanoparticles also offer potential for gene therapy treatment of large genes, with ABCA4 delivery to knockout mice showing ABCA4 production 8 months after treatment.(128)”
Koirala, A., Makkia, R. S., Conley, S. M., Cooper, M. J., & Naash, M. I. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt013 · Cited by 75
Self-citationGene therapy for Stargardt disease associated with ABCA4 gene
Han, Z., Conley, S. M., & Naash, M. I. (2014) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4614-3209-8_90 · Cited by 74
Self-citationIn Vivo Genome Editing as a Therapeutic Approach
Ho, B. X., Loh, S. J. H., Chan, W., & Soh, B.-S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092721 · Cited by 83
An Overview of the Genetics of ABCA4 Retinopathies, an Evolving Story
Al‐Khuzaei, S., Broadgate, S., Foster, C. R., Shah, M., Yu, J., Downes, S. M., & Halford, S. (2021) · Genes · doi:10.3390/genes12081241 · Cited by 85
A review of therapeutic prospects of non-viral gene therapy in the retinal pigment epithelium
Koirala, A., Conley, S. M., & Naash, M. I. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.06.002 · Cited by 71
Self-citationNovel therapeutics for Stargardt disease
Lu, L. J., Liu, J., & Adelman, R. A. (2017) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-017-3619-8 · Cited by 72
Vectors and Gene Delivery to the Retina
Planul, A., & Dalkara, D. (2017) · Annual Review of Vision Science · doi:10.1146/annurev-vision-102016-061413 · Cited by 67
In vivo genome editing as a potential treatment strategy for inherited retinal dystrophies
Yanik, M., Müller, B., Song, F., Gall, J., Wagner, F., Wende, W., Lorenz, B., & Stieger, K. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.09.001 · Cited by 66
Gene therapy for inherited retinal degenerations
Dalkara, D., & Sahel, J.-A. (2014) · Comptes Rendus. Biologies · doi:10.1016/j.crvi.2014.01.002 · Cited by 64
Zhang, W., Li, L., Su, Q., Gao, G., & Khanna, H. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.049 · Cited by 60
Mitra, R. N., Merwin, M. J., Han, Z., Conley, S. M., Al‐Ubaidi, M. R., & Naash, M. I. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.07.013 · Cited by 61
Self-citationChien, Y., Hsiao, Y.-J., Chou, S.-J., Lin, T.-Y., Yarmishyn, A. A., Lai, W.-Y., Lee, M.-S., Lin, Y.-Y., Lin, T.-W., Hwang, D.-K., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01717-x · Cited by 57
Synthesis and Characterization of Glycol Chitosan DNA Nanoparticles for Retinal Gene Delivery
Mitra, R. N., Han, Z., Merwin, M., Al Taai, M., Conley, S. M., & Naash, M. I. (2014) · ChemMedChem · doi:10.1002/cmdc.201300371 · Cited by 56
Self-citationCRB1 : One Gene, Many Phenotypes
Ehrenberg, M., Pierce, E. A., Cox, G. F., & Fulton, A. B. (2013) · Seminars in Ophthalmology · doi:10.3109/08820538.2013.825277 · Cited by 70
Stargardt macular dystrophy and evolving therapies
Hussain, R. M., Ciulla, T. A., Berrocal, A. M., Gregori, N. Z., Flynn, H. W., & Lam, B. L. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1513486 · Cited by 56
Dyka, F. M., Molday, L. L., Chiodo, V. A., Molday, R. S., & Hauswirth, W. W. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.132 · Cited by 56
Stargardt disease and progress in therapeutic strategies
Huang, D., Jeffery, R. C. H., Aung-Htut, M. T., McLenachan, S., Fletcher, S., Wilton, S. D., & Chen, F. K. (2021) · Ophthalmic Genetics · doi:10.1080/13816810.2021.1966053 · Cited by 58
Non-viral Gene Therapy for Stargardt Disease with ECO/pRHO-ABCA4 Self-Assembled Nanoparticles
Sun, D., Schur, R. M., Sears, A. E., Gao, S.-Q., Vaidya, A., Sun, W., Maeda, A., Kern, T., Palczewski, K., & Lu, Z.-R. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.09.010 · Cited by 54
Genomic DNA nanoparticles rescue rhodopsin-associated retinitis pigmentosa phenotype
Han, Z., Banworth, M. J., Makkia, R., Conley, S. M., Al‐Ubaidi, M. R., Cooper, M. J., & Naash, M. I. (2015) · The FASEB Journal · doi:10.1096/fj.15-270363 · Cited by 54
“Western blotting was performed using standard protocols as previously described (22, 29).”
BackgroundMethodSelf-citationThe roles of traditional Chinese medicine in gene therapy
Ling, C., Wang, L., Wang, Y., Zhang, Y., Yin, Z.-F., Wang, M., & Ling, C. (2014) · Journal of Chinese Integrative Medicine · doi:10.1016/s2095-4964(14)60019-4 · Cited by 54
Has retinal gene therapy come of age? From bench to bedside and back to bench
Trapani, I., & Auricchio, A. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz130 · Cited by 50
A Perspective on the Role of the Extracellular Matrix in Progressive Retinal Degenerative Disorders
Al-Ubaidi, M. R., Naash, M. I., & Conley, S. M. (2013) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.13-13536 · Cited by 51
Self-citationNon-viral therapeutic approaches to ocular diseases: An overview and future directions
Zulliger, R., Conley, S. M., & Naash, M. I. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.007 · Cited by 50
Self-citationOcular drug delivery: advancements and innovations
Tian, B., Bilsbury, E., Doherty, S., Teebagy, S., Wood, E., Su, W., Gao, G., & Lin, H. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091931 · Cited by 50
Zeng, S., Chen, Y., Zhou, F., Zhang, T., Fan, X., Chrzanowski, W., Gillies, M. C., & Zhu, L. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114965 · Cited by 53
Gene Therapy for PRPH2-Associated Ocular Disease: Challenges and Prospects
Conley, S. M., & Naash, M. I. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017376 · Cited by 51
Self-citationHarmon, B. T., Aly, A. E.-E., Padegimas, L., Sesenoglu‐Laird, O., Cooper, M. J., & Waszczak, B. L. (2014) · Gene Therapy · doi:10.1038/gt.2014.28 · Cited by 55
Self-citationTherapy Approaches for Stargardt Disease
Piotter, E., McClements, M. E., & MacLaren, R. E. (2021) · Biomolecules · doi:10.3390/biom11081179 · Cited by 49
Koirala, A., Conley, S. M., Makkia, R., Liu, Z., Cooper, M. J., Sparrow, J. R., & Naash, M. I. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.08.299 · Cited by 47
Self-citationNanoparticle-mediated miR200-b delivery for the treatment of diabetic retinopathy
Mitra, R. N., Nichols, C. A., Guo, J., Makkia, R. S., Cooper, M. J., Naash, M. I., & Han, Z. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.06.020 · Cited by 49
Self-citationGene Therapy of Inherited Retinal Degenerations: Prospects and Challenges
Trapani, I., Banfi, S., Simonelli, F., Surace, E. M., & Auricchio, A. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.030 · Cited by 47
Gene Therapy of ABCA4-Associated Diseases
Auricchio, A., Trapani, I., & Allikmets, R. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017301 · Cited by 41
Schnabolk, G., Parsons, N., Obert, E., Annamalai, B., Nasarre, C., Tomlinson, S., Lewin, A. S., & Rohrer, B. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.003 · Cited by 39
DNA nanoparticles are safe and nontoxic in non-human primate eyes
Kelley, R. A., Conley, S. M., Makkia, R., Watson, J. N., Han, Z., Cooper, M. J., & Naash, M. I. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s157000 · Cited by 36
Self-citationA Review of Gene, Drug and Cell-Based Therapies for Usher Syndrome
French, L. S., Mellough, C., Chen, F. K., & Carvalho, L. S. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00183 · Cited by 36
Stargardt-Fundus Flavimaculatus: Recent Advancements and Treatment
Abdollahi, S. H., & Hirose, T. (2013) · Seminars in Ophthalmology · doi:10.3109/08820538.2013.825286 · Cited by 32
Nuzbrokh, Y., Kassotis, A. S., Ragi, S. D., Jauregui, R., & Tsang, S. H. (2020) · Ophthalmology and Therapy · doi:10.1007/s40123-020-00287-1 · Cited by 29
Potential Therapeutic Agents Against Retinal Diseases Caused by Aberrant Metabolism of Retinoids
Liu, X., Chen, J., Liu, Z., Li, J., Yao, K., & Wu, Y. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-18429 · Cited by 32
Gene therapy for inherited retinal degenerations: initial successes and future challenges
Gupta, P. R., & Huckfeldt, R. M. (2017) · Journal of Neural Engineering · doi:10.1088/1741-2552/aa7a27 · Cited by 29
Mitra, R. N., Zheng, M., Weiss, E. R., & Han, Z. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.12.004 · Cited by 32
Self-citationThe Ocular Gene Delivery Landscape
Sahu, B., Chug, I., & Khanna, H. (2021) · Biomolecules · doi:10.3390/biom11081135 · Cited by 28
Kelley, R. A., Al‐Ubaidi, M. R., & Naash, M. I. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.624189 · Cited by 28
Self-citationABCA4-Associated Stargardt Disease
Khan, M., & Cremers, F. P. M. (2020) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-1057-9939 · Cited by 29
The utility and risks of therapeutic nanotechnology in the retina
Scheive, M., Yazdani, S., & Hajrasouliha, A. R. (2021) · Therapeutic Advances in Ophthalmology · doi:10.1177/25158414211003381 · Cited by 35
The Next Generation of Molecular and Cellular Therapeutics for Inherited Retinal Disease
Velazquez, L. A. M., & Ballios, B. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111542 · Cited by 28
Emerging Therapeutic Approaches and Genetic Insights in Stargardt Disease: A Comprehensive Review
Ghenciu, L. A., Hațegan, O. A., Stoicescu, E. R., Iacob, R., & Șișu, A. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168859 · Cited by 29
Recent Developments in Gene Therapy for Neovascular Age-Related Macular Degeneration: A Review
Finocchio, L., Zeppieri, M., Gabai, A., Toneatto, G., Spadea, L., & Salati, C. (2023) · Biomedicines · doi:10.3390/biomedicines11123221 · Cited by 34
Regenerative Nanomedicine for Vision Restoration
Zarbin, M. A., Arlow, T., & Ritch, R. H. (2013) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.05.025 · Cited by 25
Successful large gene augmentation of USH2A with non-viral episomal vectors
Toms, M., Toualbi, L., Almeida, P. V., Harbottle, R. P., & Moosajee, M. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.06.012 · Cited by 23
The Landscape of Non-Viral Gene Augmentation Strategies for Inherited Retinal Diseases
Toualbi, L., Toms, M., & Moosajee, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052318 · Cited by 23
Watson, C. M., El‐Asrag, M. E., Parry, D. A., Morgan, J., Logan, C. V., Carr, I., Sheridan, E. G., Charlton, R. S., Johnson, C. A., Taylor, G. R., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104281 · Cited by 23
The Interplay between Peripherin 2 Complex Formation and Degenerative Retinal Diseases
Tebbe, L., Kakakhel, M., Makia, M. S., Al‐Ubaidi, M. R., & Naash, M. I. (2020) · Cells · doi:10.3390/cells9030784 · Cited by 25
Self-citationBellingrath, J.-S., McClements, M. E., Fischer, M. D., & MacLaren, R. E. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1092913 · Cited by 22
Stargardt macular dystrophy and therapeutic approaches
Fujinami, K., Waheed, N. K., Laich, Y., Yang, P. G., Fujinami‐Yokokawa, Y., Higgins, J. J., Lu, J. T., Curtiss, D., Clary, C. M., & Michaelides, M. (2023) · British Journal of Ophthalmology · doi:10.1136/bjo-2022-323071 · Cited by 38
A novel RPE65 inhibitor CU239 suppresses visual cycle and prevents retinal degeneration
Shin, Y., Moiseyev, G. P., Petrukhin, K. E., Cioffi, C. L., Muthuraman, P., Takahashi, Y., & Ma, J. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.04.014 · Cited by 26
Lipid nanoparticle technology-mediated therapeutic gene manipulation in the eyes
Wang, T., Yu, T., Liu, Q., Sung, T., & Higuchi, A. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102236 · Cited by 22
Synthetic nanocarriers for the delivery of polynucleotides to the eye
Saraiva, S. M., Castro-López, V., Pañeda, C., & Alonso, M. J. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.03.001 · Cited by 21
The Future of Nanomaterials Tackling the Challenge of Delivering Nucleic Acids to the Retina
Hurst, J., Adams, F., & Schnichels, S. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202407173 · Cited by 24
CRISPR genome engineering for retinal diseases
Kantor, A., McClements, M. E., Peddle, C. F., Fry, L. E., Salman, A., Cehajic-Kapetanovic, J., Xue, K., & MacLaren, R. E. (2021) · Progress in Molecular Biology and Translational Science · doi:10.1016/bs.pmbts.2021.01.024 · Cited by 19
Rim formation is not a prerequisite for distribution of cone photoreceptor outer segment proteins
Conley, S. M., Al‐Ubaidi, M. R., Han, Z., & Naash, M. I. (2014) · The FASEB Journal · doi:10.1096/fj.14-251397 · Cited by 18
Self-citationRetinal degeneration in animal models with a defective visual cycle
Maeda, A., & Palczewski, K. (2013) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2014.01.001 · Cited by 21
Recent Advancements in Gene Therapy for Hereditary Retinal Dystrophies
Öner, A. (2017) · Turkish Journal of Ophthalmology · doi:10.4274/tjo.41017 · Cited by 22
Zheng, M., Mitra, R. N., Filonov, N. A., & Han, Z. (2015) · The FASEB Journal · doi:10.1096/fj.15-280511 · Cited by 19
Self-citationNanoparticle‐motivated gene delivery for ophthalmic application
Mitra, R. N., Zheng, M., & Han, Z. (2015) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1356 · Cited by 21
Self-citationMAPPING THE DENSE SCOTOMA AND ITS ENLARGEMENT IN STARGARDT DISEASE
Bernstein, A., Sunness, J. S., Applegate, C. A., & Tegins, E. O. (2016) · Retina · doi:10.1097/iae.0000000000001003 · Cited by 18
Novel C8orf37 mutations cause retinitis pigmentosa in consanguineous families of Pakistani origin.
Ravesh, Z., El‐Asrag, M. E., Weisschuh, N., McKibbin, M., Reuter, P., Watson, C. M., Baumann, B., Poulter, J. A., Sajid, S., Panagiotou, E. S., et al. (2015) · Europe PMC (PubMed Central) · Cited by 16
Retinal gene therapy: current progress and future prospects
Ku, C. A., & Pennesi, M. E. (2015) · Expert Review of Ophthalmology · doi:10.1586/17469899.2015.1035711 · Cited by 18
A Naturally Fluorescent Mgp Transgenic Mouse for Angiogenesis and Glaucoma Longitudinal Studies
Asokan, P., Mitra, R. N., Periasamy, R., Han, Z., & Borrás, T. (2018) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.17-22992 · Cited by 15
Self-citationClinical trials in retinal dystrophies
Eliott, D., Grob, S., Finn, A. P., & Papakostas, T. (2016) · Middle East African Journal of Ophthalmology · doi:10.4103/0974-9233.173135 · Cited by 21
Minicircle Delivery to the Neural Retina as a Gene Therapy Approach
Staurenghi, F., McClements, M. E., Salman, A., & MacLaren, R. E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911673 · Cited by 15
Metadata
- Authors
- Han, Z., Conley, S. M., Makkia, R. S., Cooper, M. J., & Naash, M. I.
- Affiliations
- University of Oklahoma Health Sciences Center (US)
- University of Oklahoma (US)
- Copernicus Therapeutics (United States) (US)
- Corresponding author
- Naash, Muna I.
- Venue
- Journal of Clinical Investigation
- Published
- 2012-09-04
- Volume
- 122
- Issue
- 9
- Pages
- 3221-3226
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3428101
- OpenAlex
- W2055017226
- Cited by
- 150
- References
- 19
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 6 · 2023: 10 · 2022: 5 · 2021: 21 · 2020: 11 · 2019: 9 · 2018: 10 · 2017: 10 · 2016: 9 · 2015: 18 · 2014: 15 · 2013: 15 · 2012: 1
- FWCI
- 6.29
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Foundation Fighting Blindness
- University of Oklahoma
- National Institutes of Health
- University of Oklahoma Health Sciences Center
- National Eye Institute (R01EY018656, R01EY022778, R01EY010609)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- DNA nanoparticles, ABCA4, Stargardt disease, gene replacement therapy, non-viral gene delivery, subretinal injection, retinal degeneration, photoreceptors, lipofuscin granules, dark adaptation
- MeSH terms
- Analysis of Variance, Animals, Corneal Dystrophies, Hereditary, DNA, Humans, Lipofuscin, Mice, Inbred C57BL, Phenotype, Genetic Therapy, Gene Expression, Mice, Knockout, ATP-Binding Cassette Transporters, Transgenes, Mice, Nanoparticles, Retinal Pigment Epithelium, Injections, Intraocular
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.